Gold Nanospheres as Inhibitors of Amyloid-β Protein Aggregation
Involved in Alzheimer’s Disease
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Alzheimer’s disease (AD) is hypothesized to be caused by the amyloid-β protein (Aβ), which
aggregates into β-sheet structure to form thick, twisted fibrils that deposit in the brain as insoluble
plaques. Thus, finding inhibitors that prevent or reduce the aggregation of Aβ would be one
therapeutic strategy for fighting this disease. Gold nanoparticles are ideal candidates for this
therapeutic strategy for AD. Nanoparticles are small enough for human cells to uptake but won’t
induce cell death.
Nanoparticles can also cross the blood-brain barrier (BBB) at low
concentrations. Thus, we investigated the inhibitory capabilities of gold nanoparticles by
performing monomer aggregation assays using gold nanospheres with three different coatings:
citrate, poly (acrylic acid) (PAA), and poly (allylamine hydrochloride) (PAH). Aβ monomer was
incubated in the presence or absence of nanospheres and agitated to promote aggregation. β-sheet
aggregates formed were monitored using thioflavin T (ThT), a fluorescent dye that binds the βsheet structure of amyloid aggregates but not random coil monomer to yield an enhanced signal.
Results demonstrate that gold nanospheres do inhibit Aβ aggregate formation, and this inhibition is
influenced by both surface coating and nanoparticle size. 18 nm PAA coated nanospheres were
identified as potent inhibitors, capable of abrogating aggregation at a substoichiometric ratio of
1:200.

Introduction
Alzheimer’s disease (AD) is a progressive neurodegenerative
disorder that results in memory loss, unusual behavior,
inabilities to think or process, and, eventually, death [1]. AD
patients also exhibit behavioral problems, such as agitation,
irritability, and aggression, which make it more difficult for
the caregivers to deal with the patients.
AD patients
eventually lose themselves in confusion, are unable to
recognize their loved ones, and gradually become unable to
carry on their basic daily function, thus requiring 24/7
standby-assistants, contributing emotional and economic
burden to their families. Because the risk of AD exacerbates
with age, and since the life expectancy is increasing, this
brings an even bigger challenge to health care. Currently, it is
estimated that there are 25-30 million AD patients worldwide,
and studies suggest that the number of AD cases will triple by
2040 [2]. With the growing population and an increasing life
expectancy, a therapeutic strategy for AD is even more dire
than ever.
This devastating disease was first discovered by and named
after Dr. Alois Alzheimer. In 1901, he admitted a 51-year old
patient, named Auguste D. with progressive memory loss,
hallucination, and delusion. Intrigued by such odd behaviors,
Dr. Alzheimer investigated her brain post-mortem and found
unusual deposits in the brain tissues that he identified as
neuritic plaques [3]. These plaques were later found to be
comprised of the amyloid-β protein (Aβ).
Soluble Aβ

monomer aggregates to form insoluble Aβ fibrils that deposit
in the brain as plaques. These cytotoxic plaques could trigger
microglial activation followed by neuritic degeneration [2].
Such degeneration leads to neuronal loss, causing the brains
of AD patients to weigh one-third less than that of normal
aging subjects [4]. Another study suggests that accumulation
of Aβ deposits at synaptic terminals may cause synaptic
damage related to cognitive decline [5]. Therefore, finding
inhibitors that prevent or reduce the aggregation of Aβ is one
therapeutic strategy for fighting this disease.
Nanoparticles have been explored for their utility in a
number of medical applications. Nanoparticles have been
used for cell imaging, targeted drug delivery, cancer
diagnostics and therapeutic applications [6]. In applications
of AD treatment, nanoparticles are attractive candidates as a
result of their demonstrated ability to penetrate the blood
brain barrier (BBB) [7]. In fact, nanoparticles have been
shown to affect Aβ aggregation. Yoo et al. demonstrate a
promotion of Aβ aggregation by N-isopropylacrylamide and
N-tert-butylacrylamide copolymeric nanoparticles as well as
cerium oxide nanoparticles. These researchers hypothesize
that electrostatic interactions between nanoparticles and
proteins lead to an increased local protein concentration in the
vicinity of the nanoparticles, which accelerates the nucleationdependent aggregation process.
In contrast, cadmium
telluride (CdTe) nanoparticles have been shown to slow the
rate of Aβ aggregation by binding protein to deplete the
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amount of free monomers available for aggregate formation
[8].
In addition, Cabaleiro-Logo et al. report that copolymeric
nanoparticles of varying hydrophobicity not only prevent
aggregation by binding to monomeric Aβ and prefibrillar
oligomers but also reverse the aggregation of Aβ fibrils
formed in absence of these nanoparticles [9].
In the current study, we explore the ability of spherical gold
nanoparticles (AuNPs) to attenuate Aβ aggregation. Spherical
AuNPs are an ideal candidate as an AD therapeutic because
they are small enough for human cells to uptake (10) and are
not cytotoxic (10, 11). In addition, AuNP can be easily
characterized
using
UV-Vis
spectrophotometry
and
transmission electron microscopy (TEM) [6].
We investigated the inhibitory capabilities of AuNPs with
three different surface coatings: citrate, poly (acrylic acid)
(PAA), and poly (allylamine hydrochloride) (PAH). We
demonstrate that both surface coating and nanoparticle size
can influence inhibitory capabilities.
Furthermore, we
identify 18 nm PAA coated AuNPs as strong inhibitors of Aβ
aggregation that are capable of abrogating aggregate
formation at a substoichiometric ratio of 1:200.

Materials and Methods
Materials
Aβ1-40 peptide, thioflavin T (ThT), and bovine serum albumin
(BSA) were purchased from Anaspec, Inc. (San Jose, CA),
Sigma (St. Louis, MO), and EMD Biosciences (San Diego,
CA), respectively.
Aβ1–40 Monomer Purification
Aβ1-40 monomer was purified to remove small aggregates that
could serve as nucleation seeds. Aβ1-40 protein was stored
desiccated at -20°C. The protein was solubilized to a
concentration of 2 mg/mL in 50 mM NaOH and purified via
size exclusion chromatography (SEC) on a Superdex 75
HR10/300 column (GE Healthcare, Buckinghamshire, UK).
Prior to Aβ1-40 monomer purification, the column was
equilibrated in 40 mM Tris-HCl, pH 8.0, and pretreated with 2
mg/mL BSA to reduce any nonspecific interaction between
the column matrix and the peptide. UV-Vis absorbance (276
nm) was used to calculate the purified Aβ1-40 monomer
concentration using an extinction coefficient
of 1450 M -1·cm -1.

from 470 nm to 500 nm. Fluorescence values were determined
as the area under the emission peak.
Aβ monomer aggregation exhibits three distinct phases:
lag, growth, and plateau. During the lag phase, nucleation
occurs, followed by a growth phase during which the amount
of β-sheet aggregate increases rapidly.
Eventually, the
aggregation process reaches a plateau, where monomers and
aggregates of different sizes are in equilibrium. An effective
inhibitor will reduce the height of the plateau. Reduction of
the equilibrium plateau for aggregate formation, PR, is
calculated as Eq. 1:

where FI is the fluorescence of the plateau observed in the
presence of the inhibitor and FC is the fluoresce of the plateau
observed for the control.
Gold Nanoparticles
8 nm and 18 nm gold nanoparticles (AuNP) were a kind
gift from the laboratory of Dr. Rahina Mahtab at South Carolina
State University. As shown in Figure 1, AuNPs with four
different coatings were tested for their inhibitory capabilities.
AuNPs were created by a series of surface overcoatings. First,
following the Frens method, the reduction of hydrogen
tetrachloroaurate (III) trihydrate (HAuCl4) by sodium citrate
created negatively charged citrate coated AuNPs. For poly
(acrylic acid) (PAA) AuNPs, 3 nm citrate AuNPs were
synthesized via the reduction of HAuCl4 by sodium borohydride
and then capped with sodium citrate. Using ascorbic acid, a
solution of HAuCl4 and hexadecyltrimethylammonium bromide
(CTAB) was weakly reduced and then added to the 3 nm seeds to
increase their diameter, growing from 8 nm to 18 nm (12). Once
the CTAB particles were created to the desired size, PAA was
overcoated onto the particles to yield negatively charged PAA
AuNPs. PAA AuNPs were overcoated to yield positively
charged poly (allylamine hydrochloride) (PAH) AuNPs.

Aβ1–40 Monomer Aggregation
SEC-purified Aβ1-40 monomer at a concentration of 40 µM
was incubated alone (control) or with 0.02 nM, 0.1 nM, or 0.2
nM gold nanoparticles in 40 mM Tris-HCl, pH 8.0. These
solutions were agitated via vortexing at 800 rpm and 25°C to
promote aggregation.
β-sheet aggregate formation was
monitored using ThT, a fluorescent dye that binds the β-sheet
structure of amyloid aggregates but not random coil monomer
to yield an enhanced signal. Periodically, an aliquot was
diluted eightfold into 10 µM ThT and the fluorescence was
measured using an LS-45 luminescence spectrometer (Perkin–
Elmer,Waltham, MA) with excitation at 450 nm and emission

Figure 1. Citrate AuNPs overcoated with CTAB, PAA, and PAH to yield
AuNPs with different surface properties.

Results and Discussion
When Aβ1-40 monomer was aggregated in the presence of
negatively charged citrate coated AuNPs, the fluorescence of
the equilibrium plateau was decreased, indicating inhibition
leading to a reduction in the extent of aggregate formation
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(Figure 2). This effect was dose dependent, ranging from no
inhibition in the presence of 0.02 nM nanoparticles to 26 ±
13% inhibition in the presence of 0.1 nM nanoparticles.
Further increase of the citrate coated nanoparticle
concentration to 0.2 nM, however, failed to increase
inhibitory capabilities.
The fluorescence of the equilibrium plateau was also
decreased when Aβ1-40 monomer was aggregated in the
presence of PAH coated AuNPs, again indicating reduced
aggregate formation (Figure 3). As for PAH coated AuNPs,
this effect was dose dependent, ranging from 8 ± 3%
inhibition in the presence of 0.025 nM nanoparticles to 42 ±
0% inhibition in the presence of 0.2 nM nanoparticles.
Furthermore, these positively charged AuNPs were more
effective inhibitors than citrate coated nanoparticles.
When Aβ1-40 monomer was aggregated in the presence of
negatively charged PAA coated AuNPs, any increase in
fluorescence was abrogated, demonstrating complete
inhibition of aggregate formation (Figure 4). Furthermore,
this effect extended down to a concentration of 0.02 nM, a
concentration that represents a substoichiometric ratio of
1:200 with Aβ1-40 monomer.

Figure 4. Aβ1-40 monomer (40 µM) was incubated in 40 mM Tris-HCl
alone (solid circles, control) or in the presence of 0.02 nM (open squares),
0.1 nM (open triangles), or 0.2 nM (open circles) PAA overcoated
AuNPs. Aggregation was induced via vortexing at 25°C and monitored
using ThT fluorescence. Results are representative of three independent
experiments.

Table 1. Inhibition of Aβ1-40 monomer aggregation by AuNPs with
citrate, PAA, and PAH coatings.

AuNP coating

Citrate

PAH

PAA
Figure 2. Aβ1-40 monomer (40 µM) was incubated in 40 mM Tris-HCl
alone (solid circle, control) or in the presence of 0.02 nM (open squares),
0.1 nM (open triangles), or 0.2 nM (open circles) citrate coated AuNPs.
Aggregation was induced via vortexing at 25°C and monitored using ThT
fluorescence.
Results are representative of three independent
experiments.

Figure 3. Aβ1-40 monomer (40 µM) was incubated in 40 mM Tris-HCl
alone (solid circles, control) or in the presence of 0.025 nM (open
squares) or 0.2 nM (open triangles) PAH overcoated AuNPs.
Aggregation was induced via vortexing at 25°C and monitored using ThT
fluorescence.
Results are representative of three independent
experiments.

[AuNP]

% Inhibition1

0.02 nM

0 ± 0%

0.1 nM

26 ± 13%

0.2 nM

30 ± 2%

0.025 nM

8 ± 3%

0.2 nM

42 ± 0%

0.02 nM

100 ± 0%

0.1 nM

100 ± 0%

0.2 nM

100 ± 0%

1

Monomer aggregation was performed in the presence of 18 nm AuNPs
as in Figures 2-4. % Inhibition was calculated as the reduction in the
fluorescence plateau at equilibrium, PR, using Eq. 1. Results represent
the average of three independent experiments.

Thus, all three surface modified AuNPs were found to
inhibit aggregation of Aβ1-40 monomer in a dose dependent
manner (Table 1). Furthermore, the extent of inhibition was
influenced by surface overcoating, with negatively charged
PAA coated nanoparticles exhibiting the most pronounced
effects. These results are in agreement with the findings of
Yoo et al. for CdTe nanoparticles [8] and Cabaleiro-Logo et al
for copolymeric nanoparticles, where inhibition of Aβ
aggregation was observed (9). These findings suggest that
surface coated AuNPs may bind monomeric or oligomeric Aβ
to reduce the concentration of the protein available for
aggregation.
To explore the effect of nanoparticle size on inhibitory
capabilities, PAA coated AuNPs with different diameters were
investigated for their ability to inhibit Aβ1-40 monomer
aggregation. When the diameter of PAA coated AuNPs was
reduced to 8 nm, their ability to inhibit Aβ1-40 aggregation was
Journal of the South Carolina Academy of Science, [2011], 9(2)

16

significantly reduced. Compared to the complete inhibition
observed in the presence of 0.2 nM PAA coated AuNPs with a
diameter of 18 nm, 8 nm PAA coated AuNPs were capable of
reducing the fluorescence plateau by only 39 ± 19% (Figure 5,
Table 2). This difference may result from the smaller surface
area presented by smaller diameter AuNPs, reducing the
ability of nanoparticles to sequester Aβ on their surface.

substoichiometric ratio represents an extremely low AuNP
inhibitor concentration, which might be effectively delivered
across the BBB. Together, these results suggest that AuNPs
should be further explored as a therapeutic strategy for AD.

Acknowledgements
Funding for this project was provided by University of South
Carolina Magellan Scholar Program and NSF-RUI grant
#CHE-0701406.

References
1.
2.
3.
4.
5.
Figure 5. Aβ1-40 monomer (40 µM) was incubated in 40 mM Tris-HCl
alone (solid circles, control) or in the presence of 8 nm (open squares) or
18 nm (open triangles) PAA overcoated AuNPs present at a concentration
of 0.2 nM. Aggregation was induced via vortexing at 25°C and
monitored using ThT fluorescence. Results are representative of three
independent experiments.
Table 2. Inhibition of Aβ1-40 monomer aggregation by 8 nm and 18 nm
PAA coated AuNPs.

AuNP diameter

[AuNP]

% Inhibition1

8 nm

0.2 nM

39 ± 19 %

18 nm

0.2 nM

100 ± 0 %

6.
7.
8.
9.

10.
11.
12.

Parihar, M. S., and Hemnani, T., Journal of Clinical Neuroscience,
2004, 11, 456.
Minati, L., Edginton, T., Bruzzone, M. G., and Giaccone, G.,
American Journal of Alzheimer’s Disease & Other Dementias,
2009, 24, 95.
Goedert, M., and Spillantini, M. G., Science, 2006, 314, 777.
LaFerla, F. M., Green, K. N., and Oddo, S., Nature, 2007, 8, 499.
Reddy, P. H., and Beal, M. F., Trends in Molecular Medicine, 2007,
14, 45.
Chithrani, B. D., Ghazani, A. A., and Chan, W. C. W., Nano Letters,
2006, 6, 662.
Kanwar, J. R., Sun, X., Punj, V., Sriramoju, B., Mohan, R. R., Zhou,
S. F., Chauhan, A., and Kanwar, R. K., Nanomedicine, 2011.
Yoo, S. I., Yang, M., Brender, J. R., Subramanian, V., Sun, K., Joo,
N. E., Jeong, S. H., Ramamoorthy, A., and Kotov, N. A.,
Angewandte Chemie International Edition, 2011, 50, 5110.
Cabaleiro-Lago, C., Quinlan-Pluck, F., Lynch, I., Lindman, S.,
Minogue, A. M., Thulin, E., Walsh, D. M., Dawson, K. A., and
Linse, S., Journal of the American Chemical Society, 2008, 130,
15437.
Connor, E. E., Mwamuka, J., Gole, A., Murphy, C. J., and Wyatt,
M. D., Small, 2005, 1, 325.
Murphy, C. J., Gole, A. M., Stone, J. W., Sisco, P. N., Alkilany, A.
M., Goldsmith, E. C., and Baxter, S. C., Accounts of Chemistry,
2008.
Jana, N. R., Gearheart, L., Murphy, C.J., Langmuir, 2001, 17, 6782.

1

Monomer aggregation was performed in the presence of PAA overcoated
AuNPs as in Figure 5. % Inhibition was calculated as the reduction in the
fluorescence plateau at equilibrium, PR, using Eq. 1. Results represent
the average of three independent experiments.

Conclusions
The current study demonstrates that surface coated gold
nanospheres are capable of inhibiting aggregation of Aβ, a
process hypothesized to play a role in the progression of AD.
Furthermore, both the surface coating and nanoparticle size
play a role in the ability of AuNPs to intervene with the
process of amyloid aggregation. These effects may stem from
variations in the ability of AuNPs to interact with Aβ
monomer or small oligomers and reduce the quantity of Aβ
available for aggregation.
Of particular significance,
complete inhibition of 40 µM Aβ1-40 monomer aggregation
was observed in the presence of 0.02 nM PAA overcoated
AuNPs. When considered relative to the low nanomolar
concentrations of Aβ present in vivo, this 1:200
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